Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
Delayed Nasdaq  -  03:47:17 2023-03-24 pm EDT
17.30 USD   -0.75%
03/154D MOLECULAR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
03/154D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
GL
03/154D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2023 03/21/2023 03/22/2023 03/23/2023 03/24/2023 Date
17.5(c) 17.68(c) 16.85(c) 17.43(c) 17.3 Last
420 019 329 920 250 651 223 005 167 155 Volume
+1.74% +1.03% -4.69% +3.44% -0.75% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 3,36 M - -
Net income 2023 -114 M - -
Net cash position 2023 177 M - -
P/E ratio 2023 -5,16x
Yield 2023 -
Sales 2024 5,22 M - -
Net income 2024 -121 M - -
Net cash position 2024 50,8 M - -
P/E ratio 2024 -5,39x
Yield 2024 -
Capitalization 579 M 579 M -
EV / Sales 2023 120x
EV / Sales 2024 101x
Nbr of Employees 140
Free-Float 86,2%
More Financials
Company
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The CompanyÔÇÖs product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The Company's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of... 
More about the company
Ratings of 4D Molecular Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about 4D MOLECULAR THERAPEUTICS, INC.
03/154D MOLECULAR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
03/154D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational High..
GL
03/154D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational High..
AQ
02/224d Molecular Therapeutics : 310 INGLAXA Phase 1/2 Interim Clinical Data Presentation &ndas..
PU
02/22Transcript : 4D Molecular Therapeutics, Inc. - Special Call
CI
02/224D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical ..
GL
02/224D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical ..
GL
02/224D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical ..
CI
02/164DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry..
GL
02/084D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Confere..
GL
02/084D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Confere..
GL
02/06SVB Securities Adjusts Price Target on 4D Molecular Therapeutics to $14 From $15, Maint..
MT
02/034d Molecular Therapeutics, Inc. : Other Events (form 8-K)
AQ
02/024D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic..
GL
02/024D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic..
CI
More news
News in other languages on 4D MOLECULAR THERAPEUTICS, INC.
02/224D Molecular Therapeutics présente les données intermédiaires des essais cliniques de p..
02/024D Molecular Therapeutics annonce l'approbation par la FDA de la demande de IND pour le..
01/094D Molecular Therapeutics, Inc. annonce des mises à jour sur son portefeuille de produi..
2022Vente d'initiés : 4D Molecular Therapeutics
2022Vente d'initiés : 4d Molecular Therapeutics
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
ETFs positioned on 4D MOLECULAR THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Invesco DWA Healthcare Momentum ETF - USD1%-4.52%United_States
HAN-GINS Indxx Healthcare Megatrend Equal W...0.92%-4.37%-NC
Virtus LifeSci Biotech Clinical Trials ETF - USD0.66%-7.05%United_States
Virtus LifeSci Biotech Products ETF - USD0.66%-3.80%United_States
Invesco DWA SmallCap Momentum ETF - USD0.45%-2.28%United_States
More ETFs positioned on 4D MOLECULAR THERAPEUTICS, INC.
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 17,43 $
Average target price 38,14 $
Spread / Average Target 119%
EPS Revisions
Managers and Directors
David H. Kirn Chief Executive Officer & Director
Fred Kamal President & Chief Operating Officer
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Peter Francis SVP-Clinical Translational R&D
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-21.52%579
MODERNA, INC.-16.81%57 628
LONZA GROUP AG18.91%43 764
SEAGEN INC.54.15%37 067
IQVIA HOLDINGS INC.-8.24%34 916
ALNYLAM PHARMACEUTICALS, INC.-19.84%23 646
Stock markets for all
100% Free Registration
fermer